Bipolar Tumor-Associated Macrophages in Ovarian Cancer as Targets for Therapy

被引:81
作者
Gupta, Vijayalaxmi [1 ]
Yull, Fiona [2 ,3 ]
Khabele, Dineo [1 ,4 ]
机构
[1] Univ Kansas, Div Gynecol Oncol, Dept Obstet & Gynecol, Med Ctr, Kansas City, KS 66160 USA
[2] Vanderbilt Univ, Dept Pharmacol, Nashville, TN 37232 USA
[3] Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA
[4] Univ Kansas, Canc Ctr, Kansas City, KS 66160 USA
关键词
ovarian cancer; tumor-associated macrophages; peritoneal metastasis; tumor microenvironment; NF-KAPPA-B; INHIBITORY FACTOR LEVELS; T-CELLS; M2; POLARIZATION; EXPRESSION; MOUSE; MICROENVIRONMENT; RECEPTOR; SERUM; LOCALIZATION;
D O I
10.3390/cancers10100366
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Ovarian cancer, a rare but fatal disease, has been a challenging area in the field of gynecological cancer. Ovarian cancer is characterized by peritoneal metastasis, which is facilitated by a cross-talk between tumor cells and other cells in the tumor microenvironment (TME). In epithelial ovarian cancer, tumor-associated macrophages (TAMs) constitute over 50% of cells in the peritoneal TME and malignant ascites, and are potential targets for therapy. Here, we review the bipolar nature of TAMs and the evolving strategies to target TAMs in ovarian cancer.
引用
收藏
页数:13
相关论文
共 81 条
  • [1] Intraepithelial T Cells and Tumor Proliferation
    Adams, Sarah F.
    Levine, Douglas A.
    Cadungog, Mark G.
    Hammond, Rachel
    Facciabene, Andrea
    Olvera, Narciso
    Rubin, Stephen C.
    Boyd, Jeff
    Gimotty, Phyllis A.
    Coukos, George
    [J]. CANCER, 2009, 115 (13) : 2891 - 2902
  • [2] Interferon signaling in ascites-associated macrophages is linked to a favorable clinical outcome in a subgroup of ovarian carcinoma patients
    Adhikary, Till
    Wortmann, Annika
    Finkernagel, Florian
    Lieber, Sonja
    Nist, Andrea
    Stiewe, Thorsten
    Wagner, Uwe
    Mueller-Bruesselbach, Sabine
    Reinartz, Silke
    Mueller, Rolf
    [J]. BMC GENOMICS, 2017, 18
  • [3] Anti-inflammatory properties of the novel antitumor agent yondelis (Trabectedin): Inhibition of macrophage differentiation and cytokine production
    Allavena, P
    Signorelli, M
    Chieppa, M
    Erba, E
    Bianchi, G
    Marchesi, F
    Olimpio, CO
    Bonardi, C
    Garbi, A
    Lissoni, A
    de Brand, F
    Jimeno, J
    D'Incalci, M
    [J]. CANCER RESEARCH, 2005, 65 (07) : 2964 - 2971
  • [4] The tumor microenvironment at a glance
    Balkwill, Frances R.
    Capasso, Melania
    Hagemann, Thorsten
    [J]. JOURNAL OF CELL SCIENCE, 2012, 125 (23) : 5591 - 5596
  • [5] The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies
    Bingle, L
    Brown, NJ
    Lewis, CE
    [J]. JOURNAL OF PATHOLOGY, 2002, 196 (03) : 254 - 265
  • [6] Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm
    Biswas, Subhra K.
    Mantovani, Alberto
    [J]. NATURE IMMUNOLOGY, 2010, 11 (10) : 889 - 896
  • [7] Two physically, functionally, and developmentally distinct peritoneal macrophage subsets
    Bou Ghosn, Eliver Eid
    Cassado, Alexandra A.
    Govoni, Gregory R.
    Fukuhara, Takeshi
    Yang, Yang
    Monack, Denise M.
    Bortoluci, Karina R.
    Almeida, Sandro R.
    Herzenberg, Leonard A.
    Herzenberg, Leonore A.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2010, 107 (06) : 2568 - 2573
  • [8] Alternatively-Activated Macrophages Upregulate Mesothelial Expression of P-Selectin to Enhance Adhesion of Ovarian Cancer Cells
    Carroll, Molly J.
    Fogg, Kaitlin C.
    Patel, Harin A.
    Krause, Harris B.
    Mancha, Anne-Sophie
    Patankar, Manish S.
    Weisman, Paul S.
    Barroilhet, Lisa
    Kreeger, Pamela K.
    [J]. CANCER RESEARCH, 2018, 78 (13) : 3560 - 3573
  • [9] M2 macrophages induce ovarian cancer cell proliferation via a heparin binding epidermal growth factor/matrix metalloproteinase 9 intercellular feedback loop
    Carroll, Molly J.
    Kapur, Arvinder
    Felder, Mildred
    Patankar, Manish S.
    Kreeger, Pamela K.
    [J]. ONCOTARGET, 2016, 7 (52) : 86608 - 86620
  • [10] Chambers SK, 1997, CLIN CANCER RES, V3, P999